Evidence map›Paper›PMID 41720938›Full record

ArticleEuropean radiology2026

The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI.

Jinhui Zhou, Siyu Ouyang, Haimei Chen, Dingyue Zhang, Yan Wang, Yuanqiang Xiao, Ying Zeng, Zebin Fang, Yufeng Wang, Lichun Chen and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jinhui Zhou *Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Siyu Ouyang *Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Haimei Chen *Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Dingyue ZhangDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yan WangRadiological Imaging Center, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China.
Yuanqiang XiaoDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ying ZengDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zebin FangDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yufeng WangDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, Meizhou, China.
Lichun ChenDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, Meizhou, China.
Jing ZhangDepartment of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tianhui ZhangDepartment of Radiology, Meizhou People's Hospital, Meizhou, China.
Xi ZhongDepartment of Radiology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Qiqi YangClinical Medical College, Xinjiang Second Medical College, Karamay, China.
XinXin BuClinical Medical College, Xinjiang Second Medical College, Karamay, China.
Yang YangOrgan Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, Guangzhou, China.
Jin WangDepartment of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. wangjin3@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-6424-8254

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515010582Guangzhou Municipal Health Commission Clinical Speciality Technology 2023P-TS47Guangzhou Municipal Research Collaborative Innovation Projects 2024A03J0283Key Research and Development Program of Guangdong Province 2019B020235002Klarmaj City Science and Technology Program (Key R&D Program) 2025BA0062National Natural Science Foundation of China grant 82271973National Natural Science Foundation of China grant 91959118The 'Five Five' Project of the Third Affiliated Hospital of Sun Yat-sen University 2023WW103
6 · The paper itself

Abstract

objectivesTo evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 ancillary features (AFs) and biomarker for hepatocellular carcinomas (HCCs) ≤ 30 mm in Western and Eastern guidelines. MATERIALS AND

methodsThis multicenter retrospective study included 1414 patients at risk for HCC who underwent MRI. The odds ratios of LI-RADS features and high alpha-fetoprotein (AFP) levels were assessed. Western and Eastern guidelines' diagnostic performances were compared via generalized estimating equations.

resultsA total of 1711 observations ≤ 30 mm were included in the extracellular contrast agent (ECA)-MRI training, internal/external ECA-MRI validation sets (n = 573, 245 and 212), internal EOB-MRI validation set (n = 681). Based on multivariable analysis, using combination of mild-moderate T2 hyperintensity and "either fat in mass or AFP ≥ 200 ng/mL," named "T2 + F/A" criterion, significantly improved the sensitivities of LR-5 v2018 (80.1-85.0% vs. 73.1-77.1%), EASL v2018 (78.4-84.3% vs. 72.2-75.7%), Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 (78.4-90.9% vs. 73.4-88.3%), Asian Pacific Association for the Study of the Liver (APASL) v2017 (81.5-94.8% vs. 73.7-90.9%) and Japan Society of Hepatology (JSH) v2021 (81.5-94.5% vs. 73.7-90.6%) for HCCs ≤ 30 mm in the training set and internal and external validation sets (all p < 0.05) without impairing specificity, except for that of Asian Pacific Association for the Study of the Liver (APASL) v2017 in the internal gadoxetic acid (EOB) validation set (75.5% vs. 77.2%, p = 0.044).

conclusionTwo LI-RADS AFs (mild-moderate T2 hyperintensity and fat in mass) and AFP ≥ 200 ng/mL are useful for improving the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm. KEY POINTS: Question The sensitivities of Western and Eastern guidelines for hepatocellular carcinoma ≤ 30 mm are still insufficient on extracellular contrast agent-enhanced MRI and gadoxetic acid-enhanced MRI. Findings The use of the integrated "T2 + F/A" diagnostic criterion significantly improved the sensitivity of Western and Eastern guidelines for HCCs ≤ 30 mm on both ECA-MRI and EOB-MRI. Clinical relevance Addressing a critical gap in noninvasive small HCC diagnosis protocols in Western and Eastern guidelines across multiple MRI contrast agents. By enabling more accurate MRI diagnosis of HCCs ≤ 30 mm, our findings could increase patients receiving curative treatments at the early stage, potentially improving outcomes.

Indexed as

Carcinoma, HepatocellularGadolinium DTPALiver NeoplasmsMagnetic Resonance ImagingAgedalpha-FetoproteinsBiomarkers, TumorContrast MediaFemaleHumansMaleMiddle AgedPractice Guidelines as TopicReproducibility of ResultsRetrospective StudiesSensitivity and Specificityalpha-FetoproteinsBiomarkers, TumorContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAAncillary featureHepatocellular carcinomaLiver Imaging Reporting and Data SystemMagnetic resonance imaging

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.